ImmunityBio
IBRX
IBRX
149 hedge funds and large institutions have $200M invested in ImmunityBio in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
5% less capital invested
Capital invested by funds: $209M → $200M (-$9.54M)
45% less call options, than puts
Call options by funds: $2.39M | Put options by funds: $4.31M
Holders
149
Holding in Top 10
–
Calls
$2.39M
Puts
$4.31M
Top Buyers
| 1 | +$3.59M | |
| 2 | +$3.06M | |
| 3 | +$2.24M | |
| 4 |
Millennium Management
New York
|
+$1.87M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.74M |
Top Sellers
| 1 | -$1.85M | |
| 2 | -$1.63M | |
| 3 | -$1.32M | |
| 4 |
BlackRock
New York
|
-$1.28M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.03M |